The NASH FibroSure test is a blood-based scoring panel used to estimate fatty liver severity, possible steatohepatitis, and liver fibrosis risk without immediately doing a liver biopsy. It is most often ordered when a person has suspected fatty liver disease, abnormal liver enzymes, obesity, type 2 diabetes, insulin resistance, high triglycerides, or imaging that shows fat in the liver. The test does not diagnose every liver condition by itself, and it does not replace a full medical evaluation. Instead, it combines several blood markers with clinical information to produce scores that help doctors decide whether liver fat looks mild or significant, whether inflammation may suggest NASH, and whether scarring may be present. A low-risk result can be reassuring, while an intermediate or high-risk result usually needs follow-up with liver enzymes, metabolic labs, imaging, elastography, or specialist review.
- NASH FibroSure estimates liver fat, liver inflammation activity, and fibrosis risk using a proprietary blood-test algorithm.
- A higher fibrosis score is usually more important than the fat score because fibrosis stage predicts long-term liver risk.
- Abnormal results do not prove cirrhosis or NASH by themselves; they guide the next step in testing.
- Fasting is often requested because glucose and triglycerides may be part of the calculation.
- Results can be misleading during acute illness, hemolysis, Gilbert syndrome, bile duct obstruction, heavy alcohol use, or sudden liver injury.
- Urgent care is needed for jaundice, confusion, vomiting blood, black stools, severe abdominal swelling, or rapidly worsening liver tests.
Table of Contents
- What the NASH FibroSure Test Measures
- Why the Test Is Ordered
- How to Read the Results
- Fibrosis Score and Liver Scarring
- Steatosis Score and Fatty Liver
- NASH Score and Liver Inflammation
- Limits, False Results, and Follow-Up
- What to Do After Abnormal Results
What the NASH FibroSure Test Measures
The NASH FibroSure test is a noninvasive blood test panel that estimates patterns seen in fatty liver disease. It does this by combining several blood markers into calculated scores. The exact formula is proprietary, so the score is not something most people can calculate by hand from a standard lab report.
The test is related to FibroTest/FibroSure-style panels, which use blood markers to estimate liver fibrosis. The NASH version adds information aimed at fatty liver disease, including steatosis and possible steatohepatitis. The older terms NAFLD and NASH are still common on lab reports and in article titles. Many medical groups now use MASLD, meaning metabolic dysfunction-associated steatotic liver disease, and MASH, meaning metabolic dysfunction-associated steatohepatitis. In everyday lab interpretation, NASH FibroSure still refers to a panel designed for fatty liver disease linked with metabolic risk.
The panel commonly uses markers such as alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma-glutamyl transferase, ALT, AST, cholesterol, triglycerides, and glucose, along with patient factors such as age, sex, height, and weight. The final report may include a fibrosis score, steatosis score, NASH score or grade, and individual component results.
These component markers overlap with routine liver and metabolic testing. For example, ALT and AST are also part of many liver enzyme evaluations, and GGT often helps interpret fatty liver, alcohol exposure, and bile duct stress. If the FibroSure report is abnormal, doctors often compare it with a broader liver function tests panel, a metabolic panel, a lipid panel, and imaging.
A helpful way to think about the test is this: NASH FibroSure does not look directly at the liver. It looks at blood patterns that tend to change when liver fat, inflammation, and scar tissue are more likely. That makes it useful for risk stratification, but not perfect for diagnosis.
Why the Test Is Ordered
Doctors order NASH FibroSure when they need more information about fatty liver risk without moving straight to biopsy. Fatty liver disease is common, and many people have no symptoms. Some discover it after an ultrasound, CT scan, or MRI mentions hepatic steatosis. Others are tested because ALT, AST, GGT, triglycerides, glucose, or insulin-related markers suggest metabolic stress.
The test is especially relevant when a person has one or more of these risk factors:
- Type 2 diabetes or prediabetes
- Obesity, especially increased waist size
- High triglycerides or low HDL cholesterol
- High blood pressure
- Insulin resistance
- Polycystic ovary syndrome
- Sleep apnea
- Persistently abnormal ALT, AST, or GGT
- Imaging that shows fatty liver
- Family history of cirrhosis, fatty liver disease, or metabolic disease
NASH FibroSure may also be ordered when a clinician wants a baseline before treatment. If someone is starting a weight-loss plan, diabetes therapy, cholesterol treatment, or a more structured fatty liver program, the score can help document starting risk. It may later be compared with repeat testing, although changes should be interpreted carefully because weight, glucose, triglycerides, bilirubin, inflammation, and lab variability can affect the result.
The test can be useful when routine liver enzymes look only mildly abnormal. A person can have important fibrosis even when ALT and AST are not dramatically high. The opposite is also true: ALT and AST can rise from exercise, muscle injury, medications, alcohol, viral illness, or other liver stress without advanced fibrosis. That is why NASH FibroSure is usually interpreted alongside ALT and AST patterns, platelet count, albumin, INR, metabolic risk factors, and imaging.
It is not usually the only test used when advanced liver disease is suspected. If there are signs of cirrhosis, portal hypertension, jaundice, fluid buildup, low platelets, abnormal INR, or low albumin, clinicians usually move to a more complete workup.
How to Read the Results
Most NASH FibroSure reports are organized around scores. The exact layout can vary by laboratory, but the report commonly maps numerical scores into interpretive categories. A score closer to 0 usually suggests a lower-risk pattern. A score closer to 1 usually suggests a higher-risk pattern. The report may also translate the score into staging language, such as no fibrosis, mild fibrosis, bridging fibrosis, or cirrhosis risk.
The three result areas are different and should not be blended together:
| Result area | What it estimates | Why it matters |
|---|---|---|
| Fibrosis score | Liver scarring risk | Fibrosis stage is one of the strongest predictors of long-term liver outcomes. |
| Steatosis score | Fat buildup in the liver | Steatosis confirms the fatty-liver pattern but does not prove severe liver disease by itself. |
| NASH score or grade | Pattern suggesting steatohepatitis | Inflammation and liver cell injury raise concern for progressive fatty liver disease. |
The fibrosis result usually deserves the closest attention. Simple fat in the liver can be reversible and may stay stable for years. Fibrosis means scar tissue has developed. As fibrosis advances, the risk of cirrhosis, liver failure, portal hypertension, and liver cancer rises.
A mild steatosis result with a low fibrosis score is different from a high steatosis result with a high fibrosis score. A high NASH score with low fibrosis may suggest active liver injury before advanced scarring has developed. A low NASH score with a high fibrosis score can happen if inflammation is less active now but prior injury has already left scar tissue.
The report should be matched to the person, not read in isolation. Age, body weight, diabetes status, alcohol intake, medications, viral hepatitis risk, autoimmune disease, iron overload, and recent illness can change the interpretation. A clinician may also compare the report with FIB-4 and APRI scores, transient elastography, ultrasound, MRI-based fat measurement, or other liver fibrosis tests.
Fibrosis Score and Liver Scarring
The fibrosis score estimates how likely scar tissue is present in the liver. In fatty liver disease, fibrosis is often staged from F0 to F4. F0 means no significant fibrosis. F1 is mild fibrosis. F2 is often considered significant fibrosis. F3 means advanced fibrosis or bridging fibrosis. F4 means cirrhosis.
A low fibrosis score generally suggests a lower chance of advanced scarring. That can be reassuring, especially if platelets, albumin, bilirubin, and INR are normal. It does not mean fatty liver should be ignored. It means the immediate risk of advanced scarring appears lower based on the test.
An intermediate score is the hardest to interpret. It may mean early scar tissue, mixed signals in the blood markers, or a result affected by another condition. Intermediate fibrosis results often lead to repeat testing, FIB-4 calculation, elastography, or referral depending on the person’s risk factors.
A high fibrosis score raises concern for advanced fibrosis or cirrhosis risk. It does not prove cirrhosis by itself, but it should not be dismissed. Doctors often follow a high score with imaging, elastography, platelet count review, albumin and INR testing, hepatitis testing, iron studies, autoimmune markers, or a hepatology referral.
Fibrosis interpretation becomes more urgent when the lab pattern includes low platelets, high bilirubin, low albumin, prolonged INR, enlarged spleen, abdominal fluid, or nodular liver imaging. Albumin and INR are especially important because they reflect liver synthetic function, not just liver cell irritation. A person with suspected advanced fibrosis may need closer monitoring than someone with only mild ALT elevation.
Fibrosis can improve, especially in earlier stages, when the cause of liver injury is addressed. Weight loss, improved insulin resistance, lower triglycerides, reduced alcohol exposure, better diabetes control, and treatment of other liver diseases can reduce ongoing injury. Cirrhosis is harder to reverse, but stabilizing the condition still matters because it can lower the risk of complications.
Steatosis Score and Fatty Liver
The steatosis score estimates how much fat buildup is likely present in the liver. Steatosis means fat has accumulated inside liver cells. It is common in people with insulin resistance, obesity, type 2 diabetes, high triglycerides, and metabolic syndrome. It can also occur with alcohol use, rapid weight changes, certain medications, malnutrition, hepatitis C, and other conditions.
A low steatosis score suggests little or no fat buildup by the test’s algorithm. If imaging showed fatty liver but the blood-based score is low, the difference may come from timing, body weight changes, fasting status, test limitations, or imaging interpretation. No single test captures every case perfectly.
A high steatosis score supports a fatty liver pattern, especially when triglycerides, glucose, insulin resistance, waist size, and liver enzymes point in the same direction. It does not automatically mean NASH, fibrosis, or cirrhosis. Many people have fatty liver without advanced scarring. The concern rises when steatosis appears together with inflammation markers, high fibrosis score, diabetes, or multiple metabolic risk factors.
Steatosis can change faster than fibrosis. Liver fat can decrease within weeks to months when calorie intake, weight, alcohol exposure, glucose control, and triglycerides improve. Fibrosis usually changes more slowly. This is why a person may see better liver enzymes or liver fat before scar-related scores improve.
Doctors often interpret the steatosis score with metabolic testing. A lipid panel helps identify high triglycerides and low HDL patterns, while fasting glucose, A1c, fasting insulin, or HOMA-IR can show insulin resistance. In many fatty liver cases, the liver result is part of a wider metabolic pattern rather than an isolated liver problem.
The practical response to a high steatosis score is usually not panic. It is a structured plan: confirm the pattern, identify metabolic drivers, reduce liver fat, and check whether fibrosis is present.
NASH Score and Liver Inflammation
The NASH score estimates whether the blood pattern is consistent with steatohepatitis. Steatohepatitis means fat in the liver is accompanied by inflammation and liver cell injury. In newer terminology, MASH is often used instead of NASH when the condition is linked to metabolic dysfunction.
NASH matters because it is more likely than simple steatosis to progress to fibrosis. Simple fatty liver can still be important, but inflammation and liver cell injury raise the level of concern. In biopsy language, doctors look for fat, ballooning injury of liver cells, lobular inflammation, and fibrosis. A blood test cannot see these features directly. It estimates the probability based on patterns in blood markers.
A low NASH score makes active steatohepatitis less likely, but it does not rule it out completely. A high NASH score suggests the liver may be under active inflammatory stress. The next step depends on the fibrosis score, liver enzymes, diabetes status, imaging, symptoms, and other causes of liver disease.
The NASH score can be affected by other reasons ALT, AST, GGT, bilirubin, glucose, or triglycerides are abnormal. Recent heavy alcohol intake, viral hepatitis, gallbladder or bile duct disease, medication injury, intense exercise, acute illness, and uncontrolled diabetes can all shift the pattern. This is why clinicians usually do not label someone with NASH based only on one blood panel.
When the NASH score is abnormal, the doctor may review alcohol use carefully, even if the main pattern looks metabolic. Alcohol and metabolic fatty liver can overlap. GGT, AST/ALT ratio, carbohydrate-deficient transferrin, PEth testing, and history may be used when alcohol exposure is a possible contributor. A related GGT and ALT pattern can help separate fatty liver, alcohol-related stress, and other liver signals, though it still needs clinical context.
The NASH score is most helpful when it changes the next decision. For example, a high NASH score plus high fibrosis score may support hepatology referral. A high NASH score with low fibrosis may support more aggressive metabolic treatment and follow-up. A borderline result may lead to repeat testing after glucose, triglycerides, weight, alcohol intake, or medication issues are addressed.
Limits, False Results, and Follow-Up
NASH FibroSure is useful, but it has limits. It is an algorithmic blood test, not a direct look at liver tissue. It estimates probability. It can understate or overstate risk when blood markers are abnormal for reasons unrelated to fatty liver.
Some situations can distort the result:
- Hemolysis, where red blood cells break down and affect haptoglobin or bilirubin
- Gilbert syndrome, which can raise unconjugated bilirubin
- Acute hepatitis or sudden liver injury
- Bile duct obstruction or cholestasis
- Recent heavy alcohol exposure
- Acute infection or inflammation
- Severe malnutrition or rapid weight loss
- Certain medications
- Uncontrolled diabetes or very high triglycerides
- Non-fasting blood draw when fasting was expected
- Lab handling problems or unusual component results
A result should also be interpreted carefully in people with known chronic liver diseases that are not primarily metabolic fatty liver disease. Viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, drug-induced liver injury, and alcohol-associated liver disease may need separate evaluation.
A common mistake is assuming that normal liver enzymes mean no fibrosis. Some people with advanced fatty liver fibrosis have normal or near-normal ALT and AST. Another mistake is assuming that a high ALT means advanced fibrosis. ALT reflects liver cell injury, not scar stage. Fibrosis risk is better judged by fibrosis scores, platelet count, imaging, elastography, and the full clinical picture.
For follow-up, clinicians may use several tools. FIB-4 is simple and uses age, AST, ALT, and platelet count. APRI uses AST and platelet count. The Enhanced Liver Fibrosis test uses a different set of direct fibrosis markers. Transient elastography estimates liver stiffness, and MRI-based tests can measure liver fat and stiffness more precisely. In selected cases, liver biopsy is still used when the diagnosis is uncertain or when the result would change treatment.
What to Do After Abnormal Results
An abnormal NASH FibroSure result should lead to a clear next step, not a vague warning. The right response depends on which part of the report is abnormal and how strongly it is abnormal.
If the fibrosis score is high, follow-up should focus on confirming or excluding advanced fibrosis. That usually means reviewing platelet count, albumin, bilirubin, INR, ultrasound findings, spleen size, and liver stiffness testing. A clinician may also check for other causes of liver disease. Hepatology referral is often appropriate when the fibrosis score suggests advanced fibrosis, when elastography is high, or when routine labs suggest reduced liver function.
If the steatosis score is high but fibrosis risk is low, the priority is usually metabolic treatment. Weight loss of about 5% can reduce liver fat for many people, while greater weight loss is often needed to improve steatohepatitis and fibrosis. The best plan is usually sustainable rather than extreme: a Mediterranean-style eating pattern, fewer sugar-sweetened drinks, fewer refined carbohydrates, higher protein and fiber intake, regular physical activity, and treatment of diabetes, triglycerides, blood pressure, and sleep apnea.
If the NASH score is high, the doctor may look for active liver injury and modifiable drivers. That can include alcohol review, medication review, diabetes control, triglyceride reduction, and checking whether ALT, AST, and GGT remain abnormal over time. If insulin resistance is part of the picture, tests such as fasting insulin, fasting glucose, A1c, or HOMA-IR can help show the metabolic pattern behind the liver result.
A practical follow-up plan may include:
- Confirm the result with the ordering clinician and review the full report, not only the highlighted score.
- Compare the result with ALT, AST, GGT, bilirubin, albumin, INR, platelets, glucose, A1c, triglycerides, and cholesterol.
- Review alcohol intake, supplements, medications, viral hepatitis risk, family history, and symptoms.
- Use imaging or elastography if fibrosis risk is intermediate or high.
- Treat metabolic risk factors and repeat selected testing on a realistic timeline.
- Seek specialist care if fibrosis risk is high, results conflict, or liver function markers are abnormal.
Urgent symptoms should not wait for routine follow-up. Yellow skin or eyes, confusion, severe sleepiness, vomiting blood, black stools, severe right upper abdominal pain, fever with jaundice, new abdominal swelling, or easy bleeding need prompt medical care.
For many people, an abnormal NASH FibroSure result becomes a turning point. It can show that fatty liver is not just an imaging note; it is part of a measurable health pattern. The most useful response is to find out whether fibrosis is present, address the metabolic drivers, and follow the result with the right level of monitoring.
References
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease 2023 (Guideline)
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) 2024 (Guideline)
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease 2021 (Guidance)
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature 2023 (Consensus Statement)
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings 2022 (Guideline)
- Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease 2006 (Validation Study)
Disclaimer
NASH FibroSure results should be interpreted by a qualified healthcare professional who can review the full report, medical history, medications, alcohol exposure, imaging, and other lab results. This article is educational and does not diagnose fatty liver disease, NASH/MASH, fibrosis, cirrhosis, or any other liver condition. Seek urgent medical care for jaundice, confusion, vomiting blood, black stools, severe abdominal swelling, or rapidly worsening symptoms.
